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Carcinosarcomas of the ovary are aggressive neoplasms account
for approximately 1% of all ovarian malignancies (Cicin et al., 2008).
Ovarian carcinosarcomas are usually diagnosed at an advanced
stage with a poor long-term prognosis. The treatment for advanced
disease consists of complete surgical staging and debulking and
postoperative chemotherapy. The optimal chemotherapy regimen is
still debated, although the majority favors a platinum-based treat-
ment. We present a patient with ovarian carcinosarcoma treated
with pegylated liposomal doxorubicin (PLD) as a second-line therapy
who had a complete response, as assessed by 18F-ﬂuorodeoxyglucose
(FDG-PET).
Case report
A 68-year-old woman diagnosed with an ovarian carcinosarcoma
was admitted to our hospital. A physical evaluation and radiology tests
revealed ascites and intestinal occlusion secondary to peritoneal carci-
nomatosis. Initial cytoreductive surgery was rejected, and she started
treatment with carboplatin (AUC 5) and paclitaxel (175 mg/m2) every⁎ Corresponding author at: Department of Medical Oncology, Hospital Infanta Sofía,
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Open access under CC BY-NC-ND license .three weeks, improving her symptoms dramatically. After she had
completed three cycles, a computer tomography (CT) scan showed a
stable disease. At that point, cytoreductive surgerywas performedwith-
out any post-surgery complications. Due to the presence of upper and
posterior right-lobe liver implants, optimal debulking could not be
achieved. A pathological analysis of the tumor implants revealed a
residual heterologous carcinosarcoma with an extent of histological
necrosis of >80%. As complementary therapy, the patient received
three cycles of the same treatment schedule.
Eight months after the diagnosis, the patient developed liver
metastases, and second-line chemotherapy treatment with PLD was
started (40 mg/m2 every four weeks) (Fig. 1). As main toxicity, she
experienced grade III palmar-plantar erythrodysesthesia (according
to the Common Terminology Criteria for Adverse Events v3.0),
which required a reduction in the dose of the drugs. A CT scan
performed after the third cycle showed that the liver lesions had
increased in size but had decreased in density, which suggested intra-
tumoral necrosis (Fig. 2). In the PDG-PET scan, no intensely increased
glucose metabolism was shown in the lesions, supporting the pres-
ence of necrosis, and no evidence of tumoral viability was reportedFig. 1. CT at diagnosis of liver metastasis.
Fig. 2. CT at revaluation after three cycles of chemotherapy: the solid lesion had
increased the size (about 42 mm), but lower density. Fig. 3. PDG-PET scan at revaluation showed no evidence of tumoral viability in the
lesions.
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able tolerance and maintained a complete response until she experi-
enced a retroperitoneal progression.Discussion
Ovarian carcinosarcomas are highly aggressive and rapidly
progressive tumors with a poor long-term prognosis (Cicin et al.,
2008). Histologically, carcinosarcomas are epithelial tumors that have
both a carcinomatous and a sarcomatous component.
Data regarding ovarian carcinosarcomas are scarce and retrospec-
tive. Although the optimal postoperative chemotherapy for ovarian car-
cinosarcoma is debatable, there is a consensus on the use of platinum-
based regimens, generally in combinationwith paclitaxel or ifosfamide.
The overall response rate (ORR) to platinum-based chemotherapy for
patients with ovarian carcinosarcoma varies between 25% and 70%,
whereas median overall survival ranges from 8 to 16 months (Cicin et
al., 2008).
There is little evidence regarding the effectiveness of second-line
therapies. In a study, single-agent ifosfamide showed an ORR of 17.9%
in patients with recurrent disease (Sutton et al., 1994). The role of
anthracycline-based chemotherapy treatment for this rare tumor entity
remains controversial. Morrow et al. (1986) showed that doxorubicin
alone had limited efﬁcacy as a ﬁrst-line treatment in this disease. To
our knowledge, the effectiveness of PLD in ovarian carcinosarcomas
has not been reported previously. Our patient had a complete response
with this agent as a second-line therapy, with an acceptable toxicity
proﬁle.
Furthermore, our case illustrates that the Response Evaluation
Criteria in Solid Tumors (RECIST) metric is unreliable in predicting
the histopathological treatment response in carcinosarcomas. In ourpatient, pathological analyses of the tissue removed during the
debulking surgery showed more than 75% pathological necrosis,
whereas the CT scan revealed stable disease. Furthermore, changes
in tumor size evaluated on the CT scan after the treatment with PLD
were poorly correlated with the metabolic changes and the tumoral
viability (and outcome). A recent study showed that FDG-PET was
signiﬁcantly more accurate than size-based criteria at assessing the
histopathological response to neoadjuvant therapy in high-grade,
soft-tissue sarcomas (Evilevitch et al., 2008). In our opinion, FDG-
PET should be considered as a modality to monitor the treatment
response in patients with carcinosarcoma of the ovary.
In conclusion, our case illustrates that PLD might have a role in the
treatment of ovarian carcinosarcoma that should be evaluated in
future studies. This case also emphasizes the need to monitor the
treatment response in these patients with FDG-PET.
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